Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test may spot hidden infections in lung cancer patients

NCT ID NCT02821949

First seen Jun 23, 2026 · Last updated Jun 23, 2026

Summary

This study looked at whether measuring procalcitonin (PCT) levels in the blood could help detect infections earlier in people with stage IV non-small cell lung cancer starting chemotherapy. Researchers enrolled 45 patients and took a PCT blood sample before their first chemo session, without telling their doctors the results. They then followed patients for 30 days to see if any developed infections. The goal was to see if PCT could be a more reliable infection marker than the standard CRP test in these patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELLS LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80054, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

procalcitonin (PCT) blood test

What this could lead to

If successful, this could provide a simple blood test to help doctors spot infections earlier in advanced lung cancer patients on chemotherapy.

What could go wrong

This is a small, early observational study with only 45 participants. It does not test any treatment, so it cannot directly improve patient outcomes.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.